CDER’s Plan For Prioritizing Safety Issues Leaves Industry Wanting More Details
Executive Summary
Pharma/biotech stakeholders push FDA for more clarity on its plans to pilot test a new system for classifying significant drug safety issues and timelines for agency action. Questions about public disclosure of FDA’s classification decisions and handling of safety issues across indications also are raised in industry comments on a draft guidance.